Insider Transactions in Q1 2023 at Aclaris Therapeutics, Inc. (ACRS)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2023
|
Douglas J. Manion Pres and CEO |
BUY
Open market or private purchase
|
Direct |
6,300
+32.98%
|
$44,100
$7.86 P/Share
|
|
Mar 09
2023
|
Douglas J. Manion Pres and CEO |
BUY
Open market or private purchase
|
Direct |
6,500
+50.0%
|
$45,500
$7.74 P/Share
|
|
Mar 03
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
30,240
-2.32%
|
$362,880
$12.63 P/Share
|
|
Mar 03
2023
|
Kevin Balthaser Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
894
-14.54%
|
$10,728
$12.63 P/Share
|
|
Mar 03
2023
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,037
-9.79%
|
$192,444
$12.63 P/Share
|
|
Mar 02
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,254
+1.38%
|
-
|
|
Mar 02
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
29,000
-2.21%
|
$348,000
$12.37 P/Share
|
|
Mar 02
2023
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+19.61%
|
-
|
|
Mar 02
2023
|
Kevin Balthaser Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,000
-17.7%
|
$12,000
$12.29 P/Share
|
|
Mar 02
2023
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+7.09%
|
-
|
|
Mar 02
2023
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,800
-8.91%
|
$177,600
$12.37 P/Share
|
|
Mar 01
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
138,425
+3.41%
|
-
|
|
Mar 01
2023
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,950
+31.72%
|
-
|
|
Mar 01
2023
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
74,675
+14.04%
|
-
|
|
Feb 15
2023
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.19%
|
$65,000
$13.06 P/Share
|
|
Feb 08
2023
|
James Loerop Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,267
-37.93%
|
$55,471
$13.89 P/Share
|
|
Feb 02
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
5,000
-0.11%
|
$80,000
$16.14 P/Share
|
|
Feb 01
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.07%
|
$400,000
$16.75 P/Share
|
|
Feb 01
2023
|
James Loerop Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+50.0%
|
-
|
|
Jan 04
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
15,000
-1.23%
|
$210,000
$14.89 P/Share
|
|
Jan 03
2023
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
25,000
-1.0%
|
$375,000
$15.68 P/Share
|